美国轻中度慢性肾脏病多学科诊疗的成本效益建模研究
该建模研究评估 Medicare 覆盖的多学科诊疗(MDC)项目对比常规诊疗在 45–84 岁 3–4 期慢性肾脏病(CKD)患者中的成本效益。MDC 额外获得 0.23(95%CI 0.08–0.42)个质量调整生命年(QALY),每 QALY 增量成本为 51,285 美元;在 150,000 美元/QALY 阈值下净货币效益为 23,100 美元(95%CI 6,252–44,323)。结论认为 Medicare 资助的 MDC 项目可减少透析需求、延长预期寿命并满足常规成本效益阈值。
要点
- MDC 较常规诊疗增加 0.23 个 QALY(95%CI 0.08–0.42)
- 每 QALY 增量成本为 51,285 美元
- 尿白蛋白排泄较高者成本效益更优
核心结论
- Medicare 资助的 MDC 项目可减少透析需求、延长预期寿命并满足常规成本效益阈值。
研究设计与样本
- 基于 Medicare 理赔数据与已发表文献构建确定性 Markov 模型,模拟 45–84 岁 3–4 期 CKD 患者终身折扣成本与 QALY。
- 比较理论性 Medicare MDC 项目(含肾脏科医生、高级执业人员、教育者、营养师、社会工作者)与常规 CKD 诊疗。
主要发现
- MDC 较常规诊疗增加 0.23 个 QALY(95%CI 0.08–0.42),每 QALY 增量成本 51,285 美元。
- 在 150,000 美元/QALY 阈值下,MDC 净货币效益为 23,100 美元(95%CI 6,252–44,323)。
- 所有亚组分析中 ICER 范围为每 QALY 42,663–72,432 美元。
- 尿白蛋白排泄较高患者中 MDC 成本效益更优;年轻患者 ICER 较高但健康改善更大。
- MDC 效果降至基线 25% 或成本增加 5 倍时仍具成本效益;95% 概率敏感性分析中每 QALY 成本低于 70,000 美元,99% 分析中低于 87,500 美元。
临床怎么用
- 对中老年 3–4 期 CKD 患者,可考虑实施 Medicare 资助的多学科诊疗以延缓透析并延长寿命。
- 尿白蛋白排泄较高者从 MDC 中获得的成本效益更优。
局限性
- 研究为理论性建模,对进展至终末期肾病低风险人群的外推性有限。
- 未研究 MDC 对住院(心血管或其他)的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multidisciplinary care (MDC) programs have been proposed as a way to alleviate the cost and morbidity associated with chronic kidney disease (CKD) in the US. METHODS AND FINDINGS: We assessed the cost-effectiveness of a theoretical Medicare-based MDC program for CKD compared to usual CKD care in Medicare beneficiaries with stage 3 and 4 CKD between 45 and 84 years old in the US. The program used nephrologists, advanced practitioners, educators, dieticians, and social workers. From Medicare claims and published literature, we developed a novel deterministic Markov model for CKD progression and calibrated it to long-term risks of mortality and progression to end-stage renal disease. We then used the model to project accrued discounted costs and quality-adjusted life years (QALYs) over patients' remaining lifetime. We estimated the incremental cost-effectiveness ratio (ICER) of MDC, or the cost of the intervention per QALY gained. MDC added 0.23 (95% CI: 0.08, 0.42) QALYs over usual care, costing $51,285 per QALY gained (net monetary benefit of $23,100 at a threshold of $150,000 per QALY gained; 95% CI: $6,252, $44,323). In all subpopulations analyzed, ICERs ranged from $42,663 to $72,432 per QALY gained. MDC was generally more cost-effective in patients with higher urine albumin excretion. Although ICERs were higher in younger patients, MDC could yield greater improvements in health in younger than older patients. MDC remained cost-effective when we decreased its effectiveness to 25% of the base case or increased the cost 5-fold. The program costed less than $70,000 per QALY in 95% of probabilistic sensitivity analyses and less than $87,500 per QALY in 99% of analyses. Limitations of our study include its theoretical nature and being less generalizable to populations at low risk for progression to ESRD. We did not study the potential impact of MDC on hospitalization (cardiovascular or other). CONCLUSIONS: Our model estimates that a Medicare-funded MDC program could reduce the need for dialysis, prolong life expectancy, and meet conventional cost-effectiveness thresholds in middle-aged to elderly patients with mild to moderate CKD.
引用
- Lin E, Chertow GM, Yan B, et al. Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study. PLoS Med. 2018. PMID: 29584720. doi:10.1371/journal.pmed.1002532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。